In the Bethesda IV group, two patients (2.8%, 2/72)—a 26-year-old man and a 50-year-old woman, both with BRAF V600E-negative thyroid nodules—developed new nodules one year and two years after ablation, respectively. The gene discussed is BRAF; the disease is thyroid nodule.